Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-α for advanced hepatocellular carcinoma -: A pilot study

被引：15

作者：

Komorizono, Y ^{[1
]}

Kohara, K ^{[1
]}

Oketani, M ^{[1
]}

Maeda, M ^{[1
]}

Shibathou, T ^{[1
]}

Shigenobu, S ^{[1
]}

Hiramine, Y ^{[1
]}

Yamasaki, N ^{[1
]}

Arima, T ^{[1
]}

Kazuaki, I ^{[1
]}

Arima, T ^{[1
]}

机构：

[1] Kagoshima Univ, Dept Internal Med 2, Fac Med, Kagoshima 8908520, Japan

来源：

DIGESTIVE DISEASES AND SCIENCES | 2003年 / 48卷 / 05期

关键词：

hepatocellular carcinoma; interferon; 5-fluorouracil; cisplatin; low dose;

D O I：

10.1023/A:1023035109665

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The purpose of this pilot study was to evaluate the efficacy and adverse events of systemic combined chemotherapy with low dose of 5-fluorouracil (250 mg/m(2), 5 days), cisplatin (10 mg/m(2), 5 days), and interferon-alpha (2.5 million units, three times weekly) for advanced hepatocellular carcinoma (HCC) underlying liver cirrhosis. Six patients who had advanced HCC with tumor thrombi in the main portal trunk were enrolled in this study. Partial response was achieved in 2, stable disease in 1, and disease progressed in 3. Objective responses were achieved in 2 (33%), however, marked decreases of alpha-fetoprotein protein and protein-induced vitamin K antagonist or absence (PIVKAII) levels were also seen in one patient (stable disease). Four patients showed hematologic or renal toxicity, which were well tolerated and managed. Our systemic combined chemotherapy resulted in favorable response and was well tolerated in those with advanced HCC underlying liver cirrhosis, complicated by leukocytopenia and thromobocytopenia.

引用

页码：877 / 881

页数：5

共 22 条

[1]

Chung YH, 2000, CANCER, V88, P1986, DOI 10.1002/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO

[2]

2-I

[3]

HUMAN-LYMPHOBLASTOID INTERFERON - INVITRO AND INVIVO STUDIES IN HEPATOCELLULAR-CARCINOMA [J].